Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
(Thomson Reuters ONE) -
PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat
cancer, today announced that it has initiated a study of its NY-ESO SPEAR(TM) T-
cells in myxoid/round cell liposarcoma (MRCLS). Patient screening is underway,
and the results from this study in up to 15 patients will inform a potential
future registration trial. The initiation of screening in this study meets a
milestone set forth in the Company's strategic collaboration agreement with
GlaxoSmithKline plc (LSE/NYSE: GSK).
This is an open-label pilot study in patients to assess preliminary safety and
efficacy in this new indication. Initially, 10 patients will be enrolled. If
further characterization of the treatment is required, up to 5 additional
patients may be enrolled. Eligible patients will be HLA-A*02:01, HLA-A*02:05
and/or HLA-A*02:06 with advanced (metastatic or inoperable) high grade MRCLS
whose tumor shows positive NY-ESO-1 expression defined as greater than or equal
to 30 percent of cells that are 2+ or 3+ by immunohistochemistry. Patients will
receive preconditioning with fludarabine and cyclophosphamide at the same dose
that is being used in Cohort 4 of the Company's ongoing synovial sarcoma study.
About MRCLS
Soft tissue sarcomas can develop from tissues like fat, muscle, nerves, fibrous
tissues, blood vessels, or deep skin tissues. There are approximately 50 types
of soft tissue sarcomas, including MRCLS. Myxoid/round cell liposarcoma is
associated with specific chromosomal translocations and represents about 30 to
35 percent of liposarcomas and 5 to 10 percent of all adult soft tissue
sarcomas. Myxoid/round cell liposarcoma commonly presents at an age ranging from
35 to 55 years.
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its SPEAR (Specific Peptide Enhanced
Affinity Receptor) T-cell platform. Established in 2008, the Company aims to
utilize the body's own machinery - the T-cell - to target and destroy cancer
cells by using engineered, increased affinity TCRs as a means of strengthening
natural patient T-cell responses. Adaptimmune's lead program is a SPEAR T-cell
therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR T-cell therapy has
demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid
tumors and in hematologic cancer types, including synovial sarcoma and multiple
myeloma. Adaptimmune has a strategic collaboration and licensing agreement with
GlaxoSmithKline for the development and commercialization of the NY-ESO TCR
program. In addition, Adaptimmune has a number of proprietary programs. These
include SPEAR T-cell therapies targeting the MAGE-A10 and AFP cancer antigens,
which both have open INDs, and a further SPEAR T-cell therapy targeting the
MAGE-A4 cancer antigen that is in pre-clinical phase with IND acceptance
targeted for 2017. The Company has identified over 25 intracellular target
peptides preferentially expressed in cancer cells and is currently progressing
12 through unpartnered research programs. Adaptimmune has over 250 employees and
is located in Oxfordshire, U.K. and Philadelphia, USA. For more
information: http://www.adaptimmune.com
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking
statements involve certain risks and uncertainties. Such risks and uncertainties
could cause our actual results to differ materially from those indicated by such
forward-looking statements, and include, without limitation: the success, cost
and timing of our product development activities and clinical trials and our
ability to successfully advance our TCR therapeutic candidates through the
regulatory and commercialization processes. For a further description of the
risks and uncertainties that could cause our actual results to differ materially
from those expressed in these forward-looking statements, as well as risks
relating to our business in general, we refer you to our Quarterly Report on
Form 10-Q filed with the Securities and Exchange Commission (SEC) on November
10, 2016, and our other SEC filings. The forward-looking statements contained in
this press release speak only as of the date the statements were made and we do
not undertake any obligation to update such forward-looking statements to
reflect subsequent events or circumstances.
Adaptimmune Contacts
Investor Relations
Will Roberts
T: (215) 825-9306
E: will.roberts(at)adaptimmune.com
Juli P. Miller, Ph.D.
T: (215) 825-9310
E: juli.miller(at)adaptimmune.com
Media Relations
Margaret Henry
T: +44 (0)1235 430036
Mobile: +44 (0)7710 304249
E: margaret.henry(at)adaptimmune.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2016 - 13:30 Uhr
Sprache: Deutsch
News-ID 510863
Anzahl Zeichen: 5779
contact information:
Town:
Philadelphia
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study"
steht unter der journalistisch-redaktionellen Verantwortung von
Adaptimmune Therapeutics plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
